British consumer products maker Reckitt Benckiser said during a first-quarter business review today that it's moving closer to carving out its struggling pharmaceutical unit and listing it as a separate public company. A strategic review of the unit that was launched last October continues, but a "capital markets solution is emerging as a strong option," Reckitt CFO Adrian Hennah told <em>Reuters</em>.
written on 16.04.2014
Reckitt CFO: Spinoff of pharma unit a 'strong option'
